Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

US Pharmaceuticals Ishares ETF (IHE)

US Pharmaceuticals Ishares ETF (IHE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family BlackRock iShares
  • Assets Under Management 1,009,120,000
  • Shares Outstanding, K 11,200
  • 60-Month Beta 0.54
  • Price/Earnings ttm 24.26
  • Annual Dividend & Yield 1.50 (1.66%)
  • Most Recent Dividend 0.585 on 12/16/25
  • Management Fee 0.39%
  • INDUSTRY GROUPING:

    ETFs - Biotech

Options Overview Details

View History
  • Implied Volatility 23.86% (-2.48%)
  • Historical Volatility 17.34%
  • IV Percentile 64%
  • IV Rank 40.08%
  • IV High 49.42% on 04/09/25
  • IV Low 6.76% on 09/03/25
  • Expected Move (DTE 7) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 16
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 146
  • Open Int (30-Day) 243
  • Expected Range 90.10 to 90.10

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.51 +6.61%
on 01/20/26
91.04 -1.03%
on 02/12/26
+4.43 (+5.17%)
since 01/12/26
3-Month
79.82 +12.88%
on 11/14/25
91.04 -1.03%
on 02/12/26
+9.67 (+12.02%)
since 11/12/25
52-Week
58.97 +52.78%
on 04/09/25
91.04 -1.03%
on 02/12/26
+19.61 (+27.82%)
since 02/12/25

Most Recent Stories

More News
Merck & Co. Stock Outlook: Is Wall Street Bullish or Bearish?

Merck & Co. has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

$SPX : 6,832.76 (-1.57%)
MRK : 119.24 (-0.06%)
IHE : 90.10 (+0.11%)
Bristol-Myers Squibb Stock Outlook: Is Wall Street Bullish or Bearish?

Bristol-Myers Squibb has lagged the broader market over the past year, but analysts are growing optimistic about the company’s outlook.

$SPX : 6,832.76 (-1.57%)
IHE : 90.10 (+0.11%)
BMY : 59.86 (-0.12%)
Viatris Stock: Is Wall Street Bullish or Bearish?

Viatris has underperformed the broader market in recent months, and analysts’ outlook remains guarded as the company executes on its transformation efforts.

TFC : 52.07 (-3.65%)
$SPX : 6,832.76 (-1.57%)
VTRS : 15.79 (-2.11%)
IHE : 90.10 (+0.11%)
Are Wall Street Analysts Predicting Bristol-Myers Squibb Stock Will Climb or Sink?

Bristol-Myers Squibb has significantly underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

$SPX : 6,832.76 (-1.57%)
IHE : 90.10 (+0.11%)
PIPR : 321.32 (-5.98%)
BMY : 59.86 (-0.12%)
How Is Bristol-Myers’ Stock Performance Compared to Other Pharma Stocks?

Bristol-Myers Squibb has notably underperformed the broader pharma space over the past year, and analysts have turned cautious on the stock’s prospects.

IHE : 90.10 (+0.11%)
REGN : 783.65 (+0.60%)
BMY : 59.86 (-0.12%)
How Is Regeneron’s Stock Performance Compared to Other Pharma Stocks?

Regeneron Pharmaceuticals has significantly underperformed the broader pharma space over the past year, yet analysts remain optimistic about the stock’s prospects.

BGNE : 184.71 (+0.49%)
IHE : 90.10 (+0.11%)
REGN : 783.65 (+0.60%)
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

Eli Lilly and Company LLY reported robust second-quarter 2025 results, wherein it beat estimates on both the top and bottom lines, driven by strong demand for its blockbuster weight loss and diabetes drugs....

NVO : 48.93 (+0.39%)
OZEM : 35.50 (-0.28%)
IHE : 90.10 (+0.11%)
LLY : 1,038.27 (+2.27%)
MEDX : 34.45 (+0.29%)
PPH : 110.30 (+0.01%)
MEDI : 30.62 (-0.71%)
Viatris Stock: Analyst Estimates & Ratings

Viatris has considerably underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

$SPX : 6,832.76 (-1.57%)
VTRS : 15.79 (-2.11%)
IHE : 90.10 (+0.11%)
GS : 904.55 (-4.24%)
Is Wall Street Bullish or Bearish on Merck Stock?

Despite Merck’s underperformance relative to the broader market over the past year, analysts continue to maintain fair confidence regarding its future potential.

WFC : 86.29 (-2.99%)
$SPX : 6,832.76 (-1.57%)
MRK : 119.24 (-0.06%)
IHE : 90.10 (+0.11%)
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook

Johnson & Johnson JNJ reported stronger-than-expected second-quarter 2025 results. The world's biggest healthcare products maker continued with its long streak of earnings beat and also exceeded revenue...

XLV : 156.00 (-0.16%)
JNJ : 244.55 (+1.53%)
IHE : 90.10 (+0.11%)
IYH : 65.09 (-0.21%)
PPH : 110.30 (+0.01%)
FTXH : 34.78 (-0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Fund Summary

The iShares U.S. Pharmaceuticals ETF seeks to track the investment results of an index composed of U.S. equities in the pharmaceuticals sector. The Fund seeks investment results that correspond to the price and yield of the Dow Jones U.S. Select Pharmaceuticals Index.

See More

Key Turning Points

3rd Resistance Point 92.58
2nd Resistance Point 91.81
1st Resistance Point 90.95
Last Price 90.10
1st Support Level 89.33
2nd Support Level 88.56
3rd Support Level 87.70

See More

52-Week High 91.04
Last Price 90.10
Fibonacci 61.8% 78.79
Fibonacci 50% 75.00
Fibonacci 38.2% 71.22
52-Week Low 58.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar